ACM
NRIX icon

ADAR1 Capital Management’s Nurix Therapeutics NRIX Stock Holding History

ADAR1 Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.6M Buy
313,236
+257,166
+459% +$4.38M 0.35% 66
2026
Q1 		$869K Sell
56,070
-16,000
-22% -$265K 0.05% 174
2025
Q4 		$1.37M Buy
72,070
+40,870
+131% +$587K 0.1% 118
2025
Q3 		$288K Hold
31,200
– – 0.03% 164
2025
Q2 		$355K Buy
31,200
+10,000
+47% +$108K 0.05% 133
2025
Q1 		$252K Buy
21,200
+10,200
+93% +$171K 0.05% 136
2024
Q4 		$207K Buy
+11,000
New +$252K 0.04% 156
2024
Q3 		– Sell
-3,500
Closed -$73K – 320
2024
Q2 		$73K Sell
3,500
-32,108
-90% -$500K 0.01% 181
2024
Q1 		$523K Buy
+35,608
New +$383K 0.12% 81

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ADAR1 Capital Management's NRIX Position: Q2 2026 in Review

ADAR1 Capital Management increased its Nurix Therapeutics (NRIX) stake by 459% in Q2 2026, buying an estimated $4.38M and bringing the position to 313,236 shares worth $7.6M. The position accounts for 0.35% of the portfolio, ranked #66.

ADAR1 Capital Management first reported a position in NRIX in Q1 2024 and has held it in 9 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • ADAR1 Capital Management held 313,236 shares of Nurix Therapeutics worth $7.6M as of Q2 2026.
  • ADAR1 Capital Management bought 257,166 Nurix Therapeutics shares in Q2 2026, an estimated $4.38M.
  • Nurix Therapeutics made up 0.35% of ADAR1 Capital Management's portfolio in Q2 2026, its #66 holding.
  • ADAR1 Capital Management first reported a position in Nurix Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.